drugset / Trial / NCT03297398
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).
Timeline
- Start
- 2018-02-21
- Primary completion
- 2019-04-18
- Completion
- 2019-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2452473 | Small molecule | 15 mg | Oral |
| Subject | LY2452473 | Small molecule | 25 mg | Oral |